Cite

HARVARD Citation

    Hong, T. et al. (2020). Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. Journal for immunotherapy of cancer. 8 (2), p. . [Online]. 
  
Back to record